Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: p47phox deficiency improves cognitive impairment and attenuates tau hyperphosphorylation in mouse models of AD

Fig. 3

p47phox deficiency attenuates tau hyperphosphorylation in the hippocampus of APP/PS1 mice and ICV-STZ mice. Representative Western blots showing tau phosphorylation at S199, T205, S396, and S404 in the hippocampus of WT, APP/PS1, Ncf1−/−, and APP/PS1-Ncf1−/− mice aged 9 months (a) and 12 months (c). The levels of non-phosphorylated tau (Tau1) and total tau (Tau5) were also measured. b, d Quantification of the immunoreactivity of Western blots, normalized against total tau. e Representative Western blots showing tau phosphorylation in the hippocampus of WT and Ncf1−/− mice receiving ICV injection of STZ or saline at the age of 6 months. f Quantification of the immunoreactivity of Western blots, normalized against total tau. One-way ANOVA: b, pS199 F (3, 13) = 4.165 p = 0.0285, pT205 F (3, 16) = 4.079 p = 0.0250, pS396 F (3, 16) = 6.366 p = 0.0048, pS404 F (3, 14) = 9.922 p = 0.0009, Tau1 F (3, 11) = 0.3631 p = 0.7810; d, pS199 F (3, 31) = 5.512 p = 0.0037, pT205 F (3, 25) = 3.722 p = 0.0243, pS396 F (3, 23) = 7.629 p = 0.0010, p-S404 F (3, 28) = 3.995 p = 0.0174, Tau1 F (3, 31) = 1.013 p = 0.4000; e, pS199 F (3, 20) = 5.508 p = 0.0064, pT205 F (3, 16) = 5.331 p = 0.0097, pS396 F (3, 19) = 3.539 p = 0.0344, pS404 F (3, 20) = 4.595 p = 0.0133, Tau1 F (3, 20) = 4.383 p = 0.0159. Both male and female mice were used. Data are mean ± SEM, with 4–6 mice in each group. *p < 0.05, **p < 0.01 compared with WT or WT ICV-Saline mice; #p < 0.05, ##p < 0.01 compared with APP/PS1 or WT ICV-STZ mice

Back to article page